We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
New Clinical Evidence Bolsters Hologic's Breast Cancer Technologies
Read MoreHide Full Article
Key Takeaways
Hologic's new studies show 3DQuorum maintains cancer detection rates across 160,000 exams.
Researchers found Hologic's Genius AI Detection tool performed similarly to radiologists on tough cases.
Hologic plans to showcase AI imaging, breast surgery tech and its next-gen Envision platform at RSNA.
Artificial intelligence (AI) is increasingly becoming a critical tool in mammography. According to a report from Towards Healthcare, the global AI in breast imaging market is expected to witness a CAGR of 3.30% through 2034, driven by the growing breast cancer prevalence and ongoing technological advancements. Hologic (HOLX - Free Report) , a women’s health-focused medical device maker, remains committed to advancing its technologies across the entire breast health continuum, with real-world studies playing an important role.
At the Radiological Society of North America (“RSNA”) 2025 Annual Meeting to be held in Chicago, IL, new data on the company’s breast cancer detection technologies will be presented. Researchers at Massachusetts General Hospital evaluated Hologic’s 3DQuorum imaging technology, which uses AI to reduce the number of 3D imaging “slices” radiologists need to review without compromising image quality, sensitivity or accuracy.
Based on more than 160,000 screening mammography exams, the retrospective study compared cancer detection rates before and after adopting 3DQuorum. The study found no significant difference in cancer detection rates after the implementation of 3DQuorum. These results suggest the technology’s potential to streamline radiologists’ workflows and save valuable time while maintaining high effectiveness in detecting cancers.
In another study, 108 radiologists from the U.K. and the United States reviewed 75 challenging breast cancer cases, and Hologic’s Genius AIDetection solution assessed the same cases. Overall, the AI technology performed similarly to radiologists. It detected more cancers but also showed lower specificity, meaning it could flag more false positives.
Hologic will also showcase its latest innovations at RSNA, including the AI-powered Genius AI Detection suite of products, advanced breast surgery technologies and the next-generation Envision Mammography Platform, set to commercially launch in fiscal 2026.
Latest News From Hologic’s Peers
QIAGEN N.V. (QGEN - Free Report) recently introduced QIAsymphony Connect, the next generation of the company’s automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting in Boston. The development builds on more than 3,000 cumulative placements of the first-generation version at the end of 2024, with the new generation designed to support liquid biopsy applications with enhanced speed, sample traceability and digital connectivity for labs.
GE Healthcare (GEHC - Free Report) introduced the Genesis Radiology Workspace, a next-generation solution designed to transform radiology workflows, unify the user experience, and empower radiologists with great efficiency and precision. Central to this innovation is Genesis View, 510(k) pending, designed to be a fast diagnostic, zero-footprint viewer, streamlining radiology workflows to enhance patient care while being fully accessible from any location.
HOLX Stock Performance, Valuation and Estimates
Year to date, Hologic shares have risen 3.8% compared with the industry’s 4.5% growth.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-sales (P/S) of 3.86X, lower than the industry average of 4.40X.
Image Source: Zacks Investment Research
See how analysts are projecting Hologic’s fiscal 2026 and 2027 earnings.
Image: Bigstock
New Clinical Evidence Bolsters Hologic's Breast Cancer Technologies
Key Takeaways
Artificial intelligence (AI) is increasingly becoming a critical tool in mammography. According to a report from Towards Healthcare, the global AI in breast imaging market is expected to witness a CAGR of 3.30% through 2034, driven by the growing breast cancer prevalence and ongoing technological advancements. Hologic (HOLX - Free Report) , a women’s health-focused medical device maker, remains committed to advancing its technologies across the entire breast health continuum, with real-world studies playing an important role.
At the Radiological Society of North America (“RSNA”) 2025 Annual Meeting to be held in Chicago, IL, new data on the company’s breast cancer detection technologies will be presented. Researchers at Massachusetts General Hospital evaluated Hologic’s 3DQuorum imaging technology, which uses AI to reduce the number of 3D imaging “slices” radiologists need to review without compromising image quality, sensitivity or accuracy.
Based on more than 160,000 screening mammography exams, the retrospective study compared cancer detection rates before and after adopting 3DQuorum. The study found no significant difference in cancer detection rates after the implementation of 3DQuorum. These results suggest the technology’s potential to streamline radiologists’ workflows and save valuable time while maintaining high effectiveness in detecting cancers.
In another study, 108 radiologists from the U.K. and the United States reviewed 75 challenging breast cancer cases, and Hologic’s Genius AIDetection solution assessed the same cases. Overall, the AI technology performed similarly to radiologists. It detected more cancers but also showed lower specificity, meaning it could flag more false positives.
Hologic will also showcase its latest innovations at RSNA, including the AI-powered Genius AI Detection suite of products, advanced breast surgery technologies and the next-generation Envision Mammography Platform, set to commercially launch in fiscal 2026.
Latest News From Hologic’s Peers
QIAGEN N.V. (QGEN - Free Report) recently introduced QIAsymphony Connect, the next generation of the company’s automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting in Boston. The development builds on more than 3,000 cumulative placements of the first-generation version at the end of 2024, with the new generation designed to support liquid biopsy applications with enhanced speed, sample traceability and digital connectivity for labs.
GE Healthcare (GEHC - Free Report) introduced the Genesis Radiology Workspace, a next-generation solution designed to transform radiology workflows, unify the user experience, and empower radiologists with great efficiency and precision. Central to this innovation is Genesis View, 510(k) pending, designed to be a fast diagnostic, zero-footprint viewer, streamlining radiology workflows to enhance patient care while being fully accessible from any location.
HOLX Stock Performance, Valuation and Estimates
Year to date, Hologic shares have risen 3.8% compared with the industry’s 4.5% growth.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-sales (P/S) of 3.86X, lower than the industry average of 4.40X.
Image Source: Zacks Investment Research
See how analysts are projecting Hologic’s fiscal 2026 and 2027 earnings.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.